Skip to content

Diode Laser and S100A8 in Peri-Implantitis

Effect of 940 nm Diode Laser as an Adjunct to Mechanical Debridement on S100A8 Levels and Clinical Parameters in Peri-Implantitis Treatment

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07524153
Enrollment
39
Registered
2026-04-13
Start date
2025-01-01
Completion date
2025-10-10
Last updated
2026-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biomarkers, Calprotectin, Periimplant Diseases, S100A8

Keywords

calprotectin, biomarkers, inflammation, Peri-implantitis

Brief summary

Purpose: The aim of this study was to compare the effectiveness of diode laser and combined treatment protocols, applied in addition to mechanical debridement, in the treatment of peri-implantitis on clinical periodontal parameters and S100A8 levels in peri-implant sulcus fluid (PISF). Methods: A total of 39 patients diagnosed with peri-implantitis were divided into three groups based on the treatment protocols used: Mechanical Debridement, Diode Laser, and Combined Treatment. Probing depth, clinical attachment level, modified plaque index, gingival index, and PISF volume measurements were recorded at baseline and at weeks 4 and 12. S100A8 levels in PISF samples were measured by ELISA.

Detailed description

This study included 39 functional implants in patients aged 30-65 diagnosed with peri-implantitis (PD ≥6 mm, no clinical mobility). Participants were assigned to three groups (n=13 per group) using simple randomization (coin toss) performed by an independent researcher: Group 1 (Mechanical debridement only), Group 2 (940 nm diode laser monotherapy), and Group 3 (Combined mechanical debridement and diode laser). Exclusion criteria consisted of systemic diseases, smoking or alcohol consumption, pregnancy/lactation, parafunctional habits, and recent use of antibiotics (within 6 months) or peri-implant treatment (within 3 months). At baseline, clinical parameters were recorded and peri-implant sulcular fluid (PISF) samples were collected. Specifically, probing depth (PD) and clinical attachment level (CAL) were measured at 6 sites per implant, while the modified plaque index (mPI) and gingival index (GI) were assessed at 4 sites per implant. Prior to PISF sampling, supragingival plaque was removed using sterile curettes, and the area was isolated and air-dried. Samples were collected from mesial and distal sites using paper strips (Ora Flow) inserted 1 mm into the sulcus for 30 seconds; contaminated strips were discarded. PISF volume was measured in microliters using a Periotron 8000 device, and samples were stored at -80°C until analysis. Treatment protocols included: mechanical debridement with titanium curettes for Group 1; decontamination using a 940 nm diode laser (2.5 W, CP2 mode, 400 μm fiber tip) for 30 seconds for Group 2; and a sequential combination of both treatments for Group 3. Following treatment, all pockets were irrigated with 10% povidone-iodine. Clinical parameters and PISF samples were evaluated at baseline (T0), week 4 (T1), and week 12 (T2). For biochemical analysis, S100A8 levels were determined via ELISA at 450 nm and calculated as ng/mL using a standard curve.

Interventions

None listed

Sponsors

Kırıkkale University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
30 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Individuals aged 30-65 years. * Presence of at least one functional dental implant with no clinical mobility * Diagnosis of peri-implantitis with a probing depth (PD) of ≥ 6 mm. * Ability to provide informed consent and attend follow-up visits.

Exclusion criteria

* Systemic diseases that may interfere with wound healing (e.g., uncontrolled diabetes). * History of radiation or chemotherapy. * Pregnancy or lactation. * Smoking or alcohol consumption. * Parafunctional habits (e.g., bruxism). * Use of systemic antibiotics within the last 6 months. * Periodontal or peri-implant treatment in the relevant area within the last 3 months.

Design outcomes

Primary

MeasureTime frameDescription
Change in S100A8 levels in Peri-Implant Sulcular Fluid (PISF)Baseline (Day 0), 28 days (Week 4), and 84 days (Week 12)S100A8 levels will be measured using an ELISA kit (ng/mL) to evaluate the inflammatory response.

Secondary

MeasureTime frameDescription
Probing Depth (PD)Baseline (Day 0), 28 days (Week 4), and 84 days (Week 12)Distance from the gingival margin to the bottom of the sulcus/pocket measured at six sites per implant/tooth. Unit of Measure: Millimeters (mm)
Clinical Attachment Level (CAL)Baseline (Day 0), 28 days (Week 4), and 84 days (Week 12)Distance from the cemento-enamel junction (CEJ) to the bottom of the pocket.Unit of Measure: Millimeters (mm)
Modified Plaque Index (mPI)Baseline (Day 0), 28 days (Week 4), and 84 days (Week 12)Assessment of plaque accumulation on the implant/tooth surfaces. Unit of Measure: Score on a scale (0 to 3)
Gingival Index (GI)Baseline (Day 0), 28 days (Week 4), and 84 days (Week 12)Assessment of gingival inflammation and bleeding tendency. Unit of Measure: Score on a scale (0 to 3)

Countries

Turkey (Türkiye)

Contacts

PRINCIPAL_INVESTIGATORAkif Nalbant, Specialist in Periodontology

Kirikkale University Faculty of Dentistry

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 14, 2026